作者
Adrian V Hernandez, Yuani M Roman, Vinay Pasupuleti, Joshuan J Barboza, C Michael White
发表日期
2020/8/18
来源
Annals of internal medicine
卷号
173
期号
4
页码范围
287-296
出版商
American College of Physicians
简介
An update is available for this article.
Background
Hydroxychloroquine and chloroquine have antiviral effects in vitro against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Purpose
To summarize evidence about the benefits and harms of hydroxychloroquine or chloroquine for the treatment or prophylaxis of coronavirus disease 2019 (COVID-19).
Data Sources
PubMed (via MEDLINE), EMBASE (via Ovid), Scopus, Web of Science, Cochrane Library, bioRxiv, Preprints, ClinicalTrials.gov, World Health Organization International Clinical Trials Registry Platform, and the Chinese Clinical Trials Registry from 1 December 2019 until 8 May 2020.
Study Selection
Studies in any language reporting efficacy or safety outcomes from hydroxychloroquine or chloroquine use in …
学术搜索中的文章
AV Hernandez, YM Roman, V Pasupuleti, JJ Barboza… - Annals of internal medicine, 2020